Total Payments
$250,539
2024 Payments
$9,250
Companies
13
Transactions
84
Payment Breakdown by Category
Research$220,165 (87.9%)
Consulting$15,742 (6.3%)
Other$7,476 (3.0%)
Travel$6,147 (2.5%)
Food & Beverage$1,010 (0.4%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $220,165 | 37 | 87.9% |
| Consulting Fee | $15,742 | 7 | 6.3% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $7,476 | 6 | 3.0% |
| Travel and Lodging | $6,147 | 18 | 2.5% |
| Food and Beverage | $1,010 | 16 | 0.4% |
Payments by Type
Research
$220,165
37 transactions
General
$30,374
47 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Lupin Inc. | $142,190 | 15 | $0 (2018) |
| Eli Lilly and Company | $55,248 | 5 | $0 (2023) |
| Glenmark Pharmaceuticals Inc. | $16,461 | 9 | $0 (2017) |
| AstraZeneca Pharmaceuticals LP | $12,481 | 22 | $0 (2024) |
| Vectura Limited | $5,831 | 2 | $0 (2019) |
| Amphastar Pharmaceuticals, Inc. | $5,000 | 1 | $0 (2024) |
| Boehringer Ingelheim Pharma GmbH & Co.KG | $4,701 | 6 | $0 (2017) |
| Boehringer Ingelheim International GmbH | $3,112 | 1 | $0 (2018) |
| Sandoz Inc. | $2,000 | 1 | $0 (2017) |
| Novartis Pharmaceuticals Corporation | $1,688 | 8 | $0 (2017) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $9,250 | 6 | Amphastar Pharmaceuticals, Inc. ($5,000) |
| 2023 | $23,451 | 14 | Eli Lilly and Company ($22,530) |
| 2022 | $36,161 | 10 | Eli Lilly and Company ($32,522) |
| 2021 | $522.52 | 2 | Seqirus USA Inc ($327.36) |
| 2019 | $4,971 | 3 | AstraZeneca Pharmaceuticals LP ($3,890) |
| 2018 | $150,066 | 18 | Lupin Inc. ($142,190) |
| 2017 | $26,117 | 31 | Glenmark Pharmaceuticals Inc. ($16,461) |
All Payment Transactions
84 individual payment records from CMS Open Payments — Page 2 of 4
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 04/08/2022 | AstraZeneca Pharmaceuticals LP | — | Food and Beverage | In-kind items and services | $75.00 | General |
| 04/08/2022 | AstraZeneca Pharmaceuticals LP | — | Food and Beverage | In-kind items and services | $45.00 | General |
| 04/08/2022 | AstraZeneca Pharmaceuticals LP | — | Travel and Lodging | In-kind items and services | $44.00 | General |
| 03/23/2022 | Eli Lilly and Company | — | — | Cash or cash equivalent | $30,158.00 | Research |
| Study: A PHASE 4, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY EVALUATING THE EFFICACY AND SAFETY OF GALCANEZUMAB VERSUS RIMEGEPANT IN ADULT PARTICIPANTS WITH EPISODIC MIGRAINE | ||||||
| 01/05/2022 | Eli Lilly and Company | — | — | In-kind items and services | $2,364.00 | Research |
| Study: A PHASE 4, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY EVALUATING THE EFFICACY AND SAFETY OF GALCANEZUMAB VERSUS RIMEGEPANT IN ADULT PARTICIPANTS WITH EPISODIC MIGRAINE | ||||||
| 11/30/2021 | Eli Lilly and Company | — | — | In-kind items and services | $195.16 | Research |
| Study: A PHASE 4, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY EVALUATING THE EFFICACY AND SAFETY OF GALCANEZUMAB VERSUS RIMEGEPANT IN ADULT PARTICIPANTS WITH EPISODIC MIGRAINE | ||||||
| 07/09/2021 | Seqirus USA Inc | — | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $327.36 | General |
| 11/26/2019 | AstraZeneca Pharmaceuticals LP | — | Consulting Fee | Cash or cash equivalent | $1,945.00 | General |
| 08/27/2019 | AstraZeneca Pharmaceuticals LP | — | Consulting Fee | Cash or cash equivalent | $1,945.00 | General |
| 06/19/2019 | Vectura Limited | — | Travel and Lodging | Cash or cash equivalent | $1,080.83 | General |
| 09/07/2018 | Vectura Limited | — | Consulting Fee | Cash or cash equivalent | $4,750.00 | General |
| 05/11/2018 | Lupin Inc. | TIOTROPIUM (Drug) | — | Cash or cash equivalent | $40,839.40 | Research |
| Study: A RANDOMIZED, DOUBLE-BLIND, DOUBLE-DUMMY, PLACEBO-CONTROLLED, CROSSOVER, MULTICENTER CLINICAL STUDY TO ASSESS THE EFFICACY AND SAFETY OF ONCE DAILY ADMINISTRATION OF LUPIN TIOTROPIUM BROMIDE INHALATION POWDER COMPARED TO SPIRIVA HANDIHALER AND PLACEBO IN PATIENTS WITH COPD INCLUDING A 12-WEEK OPEN LABEL EXTENSION TO ASSESS INHALER ROBUSTNESS • Category: PULMONARYRESPIRATORY | ||||||
| 04/23/2018 | Lupin Inc. | ADVAIR (Drug) | — | Cash or cash equivalent | $2,500.00 | Research |
| Study: A RANDOMIZED, DOUBLE-BLIND, DOUBLE-DUMMY, PLACEBO-CONTROLLED, PARALLEL-GROUP, MULTICENTER CLINICAL STUDY TO ASSESS THE EFFICACY AND SAFETY OF TWICE DAILY ADMINISTRATION OF FLUTICASONE PROPIONATE 100 MCG AND SALMETEROL XINAFOATE 50 MCG DRY POWDER INHALER COMPARED TO ADMINISTRATION WITH ADVAIR DISKUS 10050 MCG TWICE DAILY AND PLACEBO IN PATIENTS 12 YEARS OF AGE AND OLDER WITH REVERSIBLE PERSISTENT ASTHMA INCLUDING A 3-WEEK OPEN-LABEL EXTENSION TO ASSESS INHALER ROBUSTNESS • Category: PULMONARYRESPIRATORY | ||||||
| 04/20/2018 | Lupin Inc. | TIOTROPIUM (Drug) | — | Cash or cash equivalent | $7,815.00 | Research |
| Study: A RANDOMIZED, DOUBLE-BLIND, DOUBLE-DUMMY, PLACEBO-CONTROLLED, CROSSOVER, MULTICENTER CLINICAL STUDY TO ASSESS THE EFFICACY AND SAFETY OF ONCE DAILY ADMINISTRATION OF LUPIN TIOTROPIUM BROMIDE INHALATION POWDER COMPARED TO SPIRIVA HANDIHALER AND PLACEBO IN PATIENTS WITH COPD INCLUDING A 12-WEEK OPEN LABEL EXTENSION TO ASSESS INHALER ROBUSTNESS • Category: PULMONARYRESPIRATORY | ||||||
| 04/09/2018 | Lupin Inc. | TIOTROPIUM (Drug) | — | Cash or cash equivalent | $1,530.00 | Research |
| Study: A RANDOMIZED, DOUBLE-BLIND, DOUBLE-DUMMY, PLACEBO-CONTROLLED, CROSSOVER, MULTICENTER CLINICAL STUDY TO ASSESS THE EFFICACY AND SAFETY OF ONCE DAILY ADMINISTRATION OF LUPIN TIOTROPIUM BROMIDE INHALATION POWDER COMPARED TO SPIRIVA HANDIHALER AND PLACEBO IN PATIENTS WITH COPD INCLUDING A 12-WEEK OPEN LABEL EXTENSION TO ASSESS INHALER ROBUSTNESS • Category: PULMONARYRESPIRATORY | ||||||
| 04/02/2018 | Lupin Inc. | TIOTROPIUM (Drug) | — | Cash or cash equivalent | $1,300.00 | Research |
| Study: A RANDOMIZED, DOUBLE-BLIND, DOUBLE-DUMMY, PLACEBO-CONTROLLED, CROSSOVER, MULTICENTER CLINICAL STUDY TO ASSESS THE EFFICACY AND SAFETY OF ONCE DAILY ADMINISTRATION OF LUPIN TIOTROPIUM BROMIDE INHALATION POWDER COMPARED TO SPIRIVA HANDIHALER AND PLACEBO IN PATIENTS WITH COPD INCLUDING A 12-WEEK OPEN LABEL EXTENSION TO ASSESS INHALER ROBUSTNESS • Category: PULMONARYRESPIRATORY | ||||||
| 04/02/2018 | Lupin Inc. | TIOTROPIUM (Drug) | — | Cash or cash equivalent | $1,000.00 | Research |
| Study: A RANDOMIZED, DOUBLE-BLIND, DOUBLE-DUMMY, PLACEBO-CONTROLLED, CROSSOVER, MULTICENTER CLINICAL STUDY TO ASSESS THE EFFICACY AND SAFETY OF ONCE DAILY ADMINISTRATION OF LUPIN TIOTROPIUM BROMIDE INHALATION POWDER COMPARED TO SPIRIVA HANDIHALER AND PLACEBO IN PATIENTS WITH COPD INCLUDING A 12-WEEK OPEN LABEL EXTENSION TO ASSESS INHALER ROBUSTNESS • Category: PULMONARYRESPIRATORY | ||||||
| 03/23/2018 | Lupin Inc. | TIOTROPIUM (Drug) | — | Cash or cash equivalent | $9,773.48 | Research |
| Study: A RANDOMIZED, DOUBLE-BLIND, DOUBLE-DUMMY, PLACEBO-CONTROLLED, CROSSOVER, MULTICENTER CLINICAL STUDY TO ASSESS THE EFFICACY AND SAFETY OF ONCE DAILY ADMINISTRATION OF LUPIN TIOTROPIUM BROMIDE INHALATION POWDER COMPARED TO SPIRIVA HANDIHALER AND PLACEBO IN PATIENTS WITH COPD INCLUDING A 12-WEEK OPEN LABEL EXTENSION TO ASSESS INHALER ROBUSTNESS • Category: PULMONARYRESPIRATORY | ||||||
| 03/23/2018 | Lupin Inc. | TIOTROPIUM (Drug) | — | Cash or cash equivalent | $3,297.00 | Research |
| Study: A RANDOMIZED, DOUBLE-BLIND, DOUBLE-DUMMY, PLACEBO-CONTROLLED, CROSSOVER, MULTICENTER CLINICAL STUDY TO ASSESS THE EFFICACY AND SAFETY OF ONCE DAILY ADMINISTRATION OF LUPIN TIOTROPIUM BROMIDE INHALATION POWDER COMPARED TO SPIRIVA HANDIHALER AND PLACEBO IN PATIENTS WITH COPD INCLUDING A 12-WEEK OPEN LABEL EXTENSION TO ASSESS INHALER ROBUSTNESS • Category: PULMONARYRESPIRATORY | ||||||
| 03/19/2018 | Lupin Inc. | TIOTROPIUM (Drug) | — | Cash or cash equivalent | $3,900.00 | Research |
| Study: A RANDOMIZED, DOUBLE-BLIND, DOUBLE-DUMMY, PLACEBO-CONTROLLED, CROSSOVER, MULTICENTER CLINICAL STUDY TO ASSESS THE EFFICACY AND SAFETY OF ONCE DAILY ADMINISTRATION OF LUPIN TIOTROPIUM BROMIDE INHALATION POWDER COMPARED TO SPIRIVA HANDIHALER AND PLACEBO IN PATIENTS WITH COPD INCLUDING A 12-WEEK OPEN LABEL EXTENSION TO ASSESS INHALER ROBUSTNESS • Category: PULMONARYRESPIRATORY | ||||||
| 03/09/2018 | Lupin Inc. | TIOTROPIUM (Drug) | — | Cash or cash equivalent | $2,500.00 | Research |
| Study: A RANDOMIZED, DOUBLE-BLIND, DOUBLE-DUMMY, PLACEBO-CONTROLLED, CROSSOVER, MULTICENTER CLINICAL STUDY TO ASSESS THE EFFICACY AND SAFETY OF ONCE DAILY ADMINISTRATION OF LUPIN TIOTROPIUM BROMIDE INHALATION POWDER COMPARED TO SPIRIVA HANDIHALER AND PLACEBO IN PATIENTS WITH COPD INCLUDING A 12-WEEK OPEN LABEL EXTENSION TO ASSESS INHALER ROBUSTNESS • Category: PULMONARYRESPIRATORY | ||||||
| 03/06/2018 | GlaxoSmithKline, LLC. | BREO (Drug) | Food and Beverage | In-kind items and services | $14.64 | General |
| Category: RESPIRATORY | ||||||
| 03/02/2018 | Lupin Inc. | TIOTROPIUM (Drug) | — | Cash or cash equivalent | $20,245.50 | Research |
| Study: A RANDOMIZED, DOUBLE-BLIND, DOUBLE-DUMMY, PLACEBO-CONTROLLED, CROSSOVER, MULTICENTER CLINICAL STUDY TO ASSESS THE EFFICACY AND SAFETY OF ONCE DAILY ADMINISTRATION OF LUPIN TIOTROPIUM BROMIDE INHALATION POWDER COMPARED TO SPIRIVA HANDIHALER AND PLACEBO IN PATIENTS WITH COPD INCLUDING A 12-WEEK OPEN LABEL EXTENSION TO ASSESS INHALER ROBUSTNESS • Category: PULMONARYRESPIRATORY | ||||||
| 02/22/2018 | Boehringer Ingelheim International GmbH | SPIRIVA (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | In-kind items and services | $3,111.88 | General |
| Category: RESPIRATORY | ||||||
| 02/16/2018 | Lupin Inc. | TIOTROPIUM (Drug) | — | Cash or cash equivalent | $506.70 | Research |
| Study: A RANDOMIZED, DOUBLE-BLIND, DOUBLE-DUMMY, PLACEBO-CONTROLLED, CROSSOVER, MULTICENTER CLINICAL STUDY TO ASSESS THE EFFICACY AND SAFETY OF ONCE DAILY ADMINISTRATION OF LUPIN TIOTROPIUM BROMIDE INHALATION POWDER COMPARED TO SPIRIVA HANDIHALER AND PLACEBO IN PATIENTS WITH COPD INCLUDING A 12-WEEK OPEN LABEL EXTENSION TO ASSESS INHALER ROBUSTNESS • Category: PULMONARYRESPIRATORY | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| A RANDOMIZED, DOUBLE-BLIND, DOUBLE-DUMMY, PLACEBO-CONTROLLED, CROSSOVER, MULTICENTER CLINICAL STUDY TO ASSESS THE EFFICACY AND SAFETY OF ONCE DAILY ADMINISTRATION OF LUPIN TIOTROPIUM BROMIDE INHALATION POWDER COMPARED TO SPIRIVA HANDIHALER AND PLACEBO IN PATIENTS WITH COPD INCLUDING A 12-WEEK OPEN LABEL EXTENSION TO ASSESS INHALER ROBUSTNESS | Lupin Inc. | $139,690 | 14 |
| A PHASE 4, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY EVALUATING THE EFFICACY AND SAFETY OF GALCANEZUMAB VERSUS RIMEGEPANT IN ADULT PARTICIPANTS WITH EPISODIC MIGRAINE | Eli Lilly and Company | $32,717 | 3 |
| A PHASE 4 RANDOMIZED DOUBLE-BLIND PLACEBO-CONTROLLED STUDY EVALUATING THE EFFICACY AND SAFETY OF GALCANEZUMAB VERSUS RIMEGEPANT IN ADULT PARTICIPANTS WITH EPISODIC MIGRAINE | Eli Lilly and Company | $22,530 | 2 |
| GSP301-304 | Glenmark Pharmaceuticals Inc. | $16,461 | 9 |
| General Consult | Amphastar Pharmaceuticals, Inc. | $5,000 | 1 |
| A RANDOMIZED, DOUBLE-BLIND, DOUBLE-DUMMY, PLACEBO-CONTROLLED, PARALLEL-GROUP, MULTICENTER CLINICAL STUDY TO ASSESS THE EFFICACY AND SAFETY OF TWICE DAILY ADMINISTRATION OF FLUTICASONE PROPIONATE 100 MCG AND SALMETEROL XINAFOATE 50 MCG DRY POWDER INHALER COMPARED TO ADMINISTRATION WITH ADVAIR DISKUS 10050 MCG TWICE DAILY AND PLACEBO IN PATIENTS 12 YEARS OF AGE AND OLDER WITH REVERSIBLE PERSISTENT ASTHMA INCLUDING A 3-WEEK OPEN-LABEL EXTENSION TO ASSESS INHALER ROBUSTNESS | Lupin Inc. | $2,500 | 1 |
| A Randomised PhIII study to assess the effect of 100 mg SC Mepolizumab in the nasal polyp score and symptoms in subjects with bilateral Nasal polyps NP and in current need of NP surgery | GlaxoSmithKline, LLC. | $1,238 | 6 |
| A RANDOMISED PHIII STUDY TO ASSESS THE EFFECT OF 100 MG SC MEPOLIZUMAB | GlaxoSmithKline, LLC. | $28.00 | 1 |
About Dr. Craig Laforce, M.D
Dr. Craig Laforce, M.D is a Allergy & Immunology healthcare provider based in Raleigh, North Carolina. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 07/07/2005. The National Provider Identifier (NPI) number assigned to this provider is 1922005727.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Craig Laforce, M.D has received a total of $250,539 in payments from pharmaceutical and medical device companies, with $9,250 received in 2024. These payments were reported across 84 transactions from 13 companies. The most common payment nature is "" ($220,165).
Ad
Practice Information
- Specialty Allergy & Immunology
- Location Raleigh, NC
- Active Since 07/07/2005
- Last Updated 12/07/2015
- Taxonomy Code 207K00000X
- Entity Type Individual
- NPI Number 1922005727
Products in Payments
- TIOTROPIUM (Drug) $139,690
- SPIRIVA (Drug) $3,112
- STIOLTO RESPIMAT (Drug) $2,586
- ADVAIR (Drug) $2,500
- SALMETEROL XINAFOATE/FLUTICASONE PROPIONATE (Drug) $2,000
- NUCALA (Biological) $1,266
- BREZTRI (Drug) $920.88
- QVM149 (Drug) $696.00
- FEVIPIPRANT (Drug) $281.25
- BREO (Drug) $14.64
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Allergy & Immunology Doctors in Raleigh
Karen Dunn, M.d, M.D
Allergy & Immunology — Payments: $364,217
Allergy & Immunology $364,217
Jonathan Romeo, Do, DO
Allergy & Immunology — Payments: $194,805
Allergy & Immunology $194,805
Dr. Laurie Mcwilliams, M.d, M.D
Allergy & Immunology — Payments: $93,811
Allergy & Immunology $93,811
Sonia Bains, Md, MD
Allergy & Immunology — Payments: $45,272
Allergy & Immunology $45,272
Gurvinder Deogun, Md, MD
Allergy & Immunology — Payments: $14,174
Allergy & Immunology $14,174
Dr. Maureen Petersen, M.d, M.D
Allergy & Immunology — Payments: $12,785
Allergy & Immunology $12,785